Sartorius Stedim Biotech: Biopharmaceutical Expert Dr. Christel Fenge is New VP of Marketing, Fermentation Technologies

| Print |
Wednesday, 13 October 2010 17:20 (UTC + 2)

sarto-stedim-bio_logo

Goettingen, Germany and Aubagne, France, October 13, 2010 / b3c newswire / – Dr. Christel Fenge joined the Sartorius Stedim Biotech group as Vice President of Marketing for Fermentation Technologies. She will be globally responsible for the management of the product portfolio of multi- and single-use bioreactors, which currently represents the most comprehensive range in the industry.

 

Most recently Christel Fenge held the position as the General Manager of Recipharm Biologics. Previous posts included senior management positions in biopharmaceutical development at AstraZeneca. She started her industrial career in cell culture process development at Pharmacia & Upjohn and in product management at B.Braun Biotech. Christel Fenge received her doctorate in Biochemistry from the University of Hanover, Germany.

 

“We are extremely pleased to have Dr. Fenge join our organization to strengthen our Fermentation Technology activities, particularly with regard to implementing and supporting our single-use technology approach she will play an essential role,” explained Reinhard Vogt, Member of the Board of Sartorius Stedim Biotech. “She brings with her an exceptional experience base of cell culture and protein science, which will further our customer support and technology bases.”

 

Current image file:

Dr. Christel Fenge, Vice President of Marketing, Fermentation Technologies at Sartorius Stedim Biotech:

http://www.sartorius.com/media/content/press/support/Christel_Fenge.jpg

 


A profile of Sartorius Stedim Biotech - www.sartorius-stedim.com

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.” Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approximately 2,400 people, and in 2009 earned sales revenue of 401.2 million euros.

 

 

Contact: Dominic Grone; Group Corporate Communications;

Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany;

Phone: +49 (0)551.308.3324; Fax: +49 (0)551.308.3572;

e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it ; www.sartorius-stedim.com